Unpublished conference/Abstract (Scientific congresses and symposiums)
MSC in clinics: Liver Transplantation
DETRY, Olivier
20145th Expert Meeting
 

Files


Full Text
Detry.MISOT2014.pdf
Publisher postprint (15.81 MB)
Download
Annexes
MISOT V 2014 - Flyer-final.pdf
Publisher postprint (4.59 MB)
Download
MiSOT V Scientific-program-final.pdf
Publisher postprint (167.72 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
organ transplantation
Abstract :
[en] For several years, mesenchymal stem cells (MSC) have been evaluated in vivo and in vitro for their immunomodulatory, anti-inflammatory, anti- ischemia-reperfusion injury and “tissue repair” properties. These characteristics could make them interesting in various clinical applications, and particularly in organ transplantation. Taking advantage of our centre expertise and experience concerning MSC use in graft-versus-host disease after bone marrow transplantation and using already functioning GMP-compliant laboratory able to produce clinical-grade MSC, we initiated in 2011 a first trial exploring safety and tolerability of third party MSC infusions after kidney or liver transplantation in a prospective phase I-II study. In this study, after successful transplantation, 10 liver and 10 kidney transplant recipients under standard immunosuppressive treatment (tacrolimus, mycophenolate, steroids) receive an intravenous infusion of 1.5 - 3x106/kg of third-party MSC, on post-operative day 3+/-2. These patients are prospectively compared to the same number of liver and kidney transplant recipients who meet inclusion criteria but do not receive MSC infusion. Safety is assessed by recording side effects, including opportunistic infections and cancers. Immunosuppressive potential is evaluated by rejection episode rates, graft/patient survivals, immunohistology of 3-month (kidney) and 6-month (liver) graft biopsies, and in vitro evaluation of recipient immunity profile. In a second step, reduction (kidney) and progressive weaning (liver) of immunosuppression is attempted in recipients who received MSC. Inclusion of liver patients is now complete, and to date 3 kidney patients received MSC. Primary results will be presented, and complete 6-month liver results are expected for the end of 2014. The next step will be to assert the immunosuppressive potential of MSC after organ transplantation, and the opportunity to develop larger randomised, controlled, phase III trials.
Disciplines :
Surgery
Author, co-author :
DETRY, Olivier  ;  Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Language :
English
Title :
MSC in clinics: Liver Transplantation
Publication date :
21 March 2014
Event name :
5th Expert Meeting
Event organizer :
MISOT (MSC in solid organ transplantation)
Event place :
Bergamo, Italy
Event date :
du 20 au 21 mars 2014
By request :
Yes
Audience :
International
Available on ORBi :
since 21 April 2014

Statistics


Number of views
71 (14 by ULiège)
Number of downloads
907 (13 by ULiège)

Bibliography


Similar publications



Contact ORBi